Clinical Trial

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Study acronym: ASCEND
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-22; most recent amendment 2026-03-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-17
Trial Details
NCT Number NCT07199335
Lead Sponsor Massachusetts General Hospital
Collaborators: ViiV Healthcare, Fenway Community Health
Conditions HIV, Substance Use Disorder (SUD), Injection Drug Use
Enrollment 100 participants
Start Date 2026-02-24
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-19